A personalized platform identifies trametinib plus zoledronate for a patient with KRAS-mutant metastatic colorectal cancer

Colorectal cancer remains a leading source of cancer mortality worldwide. Initial response is often followed by emergent resistance that is poorly responsive to targeted therapies, reflecting currently undruggable cancer drivers such as KRAS and overall genomic complexity. Here, we report a novel ap...

Descripción completa

Detalles Bibliográficos
Autores principales: Bangi, Erdem, Ang, Celina, Smibert, Peter, Uzilov, Andrew V., Teague, Alexander G., Antipin, Yevgeniy, Chen, Rong, Hecht, Chana, Gruszczynski, Nelson, Yon, Wesley J., Malyshev, Denis, Laspina, Denise, Selkridge, Isaiah, Rainey, Hope, Moe, Aye S., Lau, Chun Yee, Taik, Patricia, Wilck, Eric, Bhardwaj, Aarti, Sung, Max, Kim, Sara, Yum, Kendra, Sebra, Robert, Donovan, Michael, Misiukiewicz, Krzysztof, Schadt, Eric E., Posner, Marshall R., Cagan, Ross L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531007/
https://www.ncbi.nlm.nih.gov/pubmed/31131321
http://dx.doi.org/10.1126/sciadv.aav6528

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531007/
https://www.ncbi.nlm.nih.gov/pubmed/31131321
http://dx.doi.org/10.1126/sciadv.aav6528

Ejemplares similares